Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2009 on request of the sponsor.

On, 20 November 2001 orphan designation (EU/3/01/064) was granted by the European Commission to Icon Clinical Research UK Ltd., United Kingdom, for abetimus sodium for the treatment of lupus nephritis.

The sponsorship was transferred to La Jolla Limited, United Kingdom in September 2005.

Key facts

Active substance
Abetimus sodium
Disease / condition
Treatment of lupus nephritis
Date of first decision
EU designation number

Sponsor's contact details

La Jolla Limited,
20-22 Bedford Row,
London WC1R 4JS,
United Kingdom
Telephone: +44 20 7400 3333
Telefax: +44 20 7400 3366

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating